Editorial & Opinion
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib.
| العنوان: | The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib. |
|---|---|
| المؤلفون: | Duchemann B; Medical and Thoracic Oncology, HUPSSD Avicenne Hospital APHP, Bobigny, France.; INSERM UMR1272, Paris 13, the University Sorbonne Paris Nord, Bobigny, France., Fabre E; Biochemistry Department AP-HP, HUPSSD Avicenne Hospital APHP, Bobigny, France., Remon J; Department of Cancer Medicine, Paris-Saclay University, Gustave Roussy, Villejuif, France. |
| المصدر: | Translational lung cancer research [Transl Lung Cancer Res] 2024 Apr 29; Vol. 13 (4), pp. 952-955. Date of Electronic Publication: 2024 Apr 24. |
| نوع المنشور: | Editorial; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Hong Kong] : Pioneer Bioscience Publishing Company, [2012]- |
| مستخلص: | Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-30/coif). J.R. reports receipt of grants/research support from MSD, Astra-Zeneca (EORTC), Sanofi (EORTC); support for attending meetings or travel from OSE immunopharmaceutic. Honoraria or consultant fees as advisory boards (all institutions) from AstraZeneca, EDIMARK; sponsored research (all institutions) from MERCK; other support/potential conflicts of interest: as speaker educational/webinars for AstraZeneca, Sanofi, Takeda Roche, and Janssen; and other non-financial interests as Secretary of EORTC-LCG. B.D. reports that he has been involved in the advisory board of Roche, Pfizer, Astra Zeneca, Chiesi, Amgen, Lilly, Medscape, MSD, and Sanofi, and he received travel support from Oxyvie. The other author has no conflicts of interest to declare. |
| التعليقات: | Comment on: Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. (PMID: 36913537) |
| References: | Cancers (Basel). 2023 Mar 07;15(6):. (PMID: 36980522) Lancet. 2016 Apr 2;387(10026):1415-1426. (PMID: 26777916) Nat Commun. 2022 Nov 10;13(1):6791. (PMID: 36357385) Ann Oncol. 2023 Apr;34(4):339-357. (PMID: 36872130) Ann Oncol. 2021 Dec;32(12):1637-1642. (PMID: 34481037) Oncotarget. 2016 Nov 29;7(48):78985-78993. (PMID: 27738317) J Thorac Oncol. 2024 Feb;19(2):240-251. (PMID: 37806385) Clin Cancer Res. 2019 Jan 1;25(1):158-165. (PMID: 30224342) Clin Cancer Res. 2019 Nov 1;25(21):6382-6391. (PMID: 31182434) Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. (PMID: 36913537) Nature. 2021 Sep;597(7878):732-737. (PMID: 34526717) Cancer Cell. 2022 Jul 11;40(7):754-767.e6. (PMID: 35820397) Clin Cancer Res. 2021 Oct 1;27(19):5258-5271. (PMID: 34301751) |
| تواريخ الأحداث: | Date Created: 20240513 Latest Revision: 20240514 |
| رمز التحديث: | 20240514 |
| مُعرف محوري في PubMed: | PMC11082718 |
| DOI: | 10.21037/tlcr-24-30 |
| PMID: | 38736503 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2218-6751 |
|---|---|
| DOI: | 10.21037/tlcr-24-30 |